




版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Recent Advances in HIV Vaccine DevelopmentContentI. IntroductionII. Several human trialsIII. Antibodies inducing strategy bNAbs (broadly neutralizing antibodies) HIV Env trimer Epitope-based immunogen designsIV. T cell response strategy Multivalent mosaic proteins Conserved elements immunogens CMV v
2、ector: atypical CD8 responseI. IntroductionHighly active anti-retroviral therapy (HAART)Immune escape: Attack CD4+ T cell Highly antigenic variation ProvirusStructure : ImmunogenCr: WikipediaCr: WikipediaII. Several human trials1. Whole inactivated viruses & Live attenuated virusesSecurity: Cause in
3、fectiousEfficiency: No evidenceDelete genes related to duplicate: No advance2. Subunit vaccineMembrane proteinMonomer or polypeptideSecurity: noninfectiousEfficiency: Highly variable Neutralizing antibody spectrum is narrowVax Gen:gp120 vaccine No vaccine efficacy3. Vector virus vaccineT cell immuni
4、ty to HIVPox viruses & Adenoviruses(Ad5)MRKAd5 HIV-1 Gag/Pol/Nef Poor efficacy Risk of viral acquisition increasedRV-144:Canarypox vector (Gag/Pol/Env)/gp120Prime-BoostCombined vaccination31.2% vaccine efficacy (at 42 months)The importance of Abs: IgG:inversely correlated with risk of acquisition Ig
5、A: positive correlation nNAbs(non-neutralizing antibodies): Neither bNAbs,nor CTL ADCC4. DNA vaccineHVTN 505Prime: DNA vaccine Clade B-Gag/Pol/Nef Clade A/B/C-EnvBoost:Ad5 Clade B-Gag/Pol Clade A/B/C-Env No efficacyThe HIV vaccine efficacy trials6 So Youn Shin. Recent update in HIV vaccine developme
6、nt. Cin Exp Vaccine Res.2016;5:6-11III. Antibodies inducing strategybNAbs (broadly neutralizing antibodies)Neutralize most prevalent HIV strains VRC01、PGT13510%-30%:2-4 years after infectionEfficacy in preventing infection Decrease the load of vival Bind to Env trimerThe broad neutralization capabil
7、ity of VRC019 Peter D K, John R M, Gary J N. The changing face of HIV vaccine research. Journal of the international AIDS society 2012,15:17407HIV glycoprotein spike7 Barton F. Haynes. New approaches to HIV vaccine development. Curr Opin Immuno. 2015. 35:39-47.Characteristics of bNAbs10%-30%: Higher
8、 frequency of T follicular helper cellHigh degree of somatic mutationbNAbs are disfavored: Poly- and auto-reactivity Immune tolerance controlMaturation of broadly neutralizing HIV-1 immunity9 Peter D K, John R M, Gary J N. The changing face of HIV vaccine research. Journal of the international AIDS
9、society 2012,15:17407Antibody-virus co-evolution10Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013; 496(7446):469476. How to induce bNAbs 1)Target bNAbs B cell lineages: Activation of B-cell lineage to yield bNAbs VRC01:Break the
10、glycosylation cite2)Epitope-based immunogen designs: HIV Env trimer2. HIV Env trimerNative HIV Env trimer: Antigenic diversity Consealing critical epitope Somatic hypermutation Effective immunogenEpitope-based immunogen designs: Stable Mimics the native trimer of bNAbs epitopes Expose as many bNAb e
11、pitopes as possibleEpitope-based immunogen designsBG505 SOSIP. 664 gp140Highly stableClosely resemble native virus spikesMultiple neutralizing epitopes were highly reactive with theBG505Biophysical characterization of BG505 SOSIP.664 gp140 trimers3 Rogier W. A Next-Generation Cleaved, Soluble HIV-1
12、Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. PLoS Pathog. 2013.9(9): e1003618. BG505 SOSIP.664 gp140 trimer antigenicity by negative stain EM.3 Rogier W. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.6
13、64 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. PLoS Pathog. 2013.9(9): e1003618. BG505.T332N virus neutralization and ELISA binding to BG505 SOSIP.664 gp140 trimers by bNAbs or non-NAbs.3 Rogier W. A Next-Generation Cleaved, Soluble HIV-1 Env Trim
14、er, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. PLoS Pathog. 2013.9(9): e1003618. IV. T cell response strategyCD8+ T cell: Kill HIV-infected T cellDifficulties: Variability CTL escape mutant3 strategies: Multivalent mosaic proteins
15、 Conserved-epitopes CMV vector1. Multivalent mosaic proteinsMaximize the coverage of potential T cell epitopesMosaic HIV-1 Gag/Pol/Env (rAd26 vector)Expand both the breadth and depth of T cell responses Breadth and magnitude of epitope-specific T lymphocyte responses to PTE peptides.1Barouch D H. Mo
16、saic HIV-1 vaccines expand the breath and depth of cellular immune responses in rhesus monkeysJ. Nat Med,2010,16(3):319-232. Conserved-epitopesTarget the most conserved region of HIVNYVAC vector: Consensus Env Trivalent mosaic Env proteinAverage coverage of 9-mers by three HIV-1 Env immunogens.8 Hul
17、ot S.L。 Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 Group M consensus, and trivalent mosaic envelope vaccines formulated as a DNA prime, NYVAC, and envelope protein boos. Journal of Virology 2015 3. CD8+T cell:CMV vectorsRhesus cytomegalovirus (rhCMV) vectors Geneti
18、cally programmed: Absence of the Rh157.5, Rh157.4, and Rh157.6CD8+Tcellepitoperecognition: Promiscuous MHC class I- and class II-restricted CD8+ T cell responses CD8-MHC class II cytotoxic T cell responseV. References1Barouch D H, Obrien K L, Simmons N L, et al. Mosaic HIV-1 vaccines expand the brea
19、th and depth of cellular immune responses in rhesus monkeysJ. Nat Med,2010,16(3):319-232 N. Borthwick, T. Ahmed, B. Ondondo et al.Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Molecular Therapy, 2014,22(2), 464753 Rogier W. Sanders, Ronald Derking, Albert Cupo,
20、et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. PLoS Pathog. 2013.9(9): e1003618. doi:10.1371/journal.ppat.10036184 Hansen SG, Sacha JB, Hughes CM, et al. Cytomegalovirus vect
21、ors violate CD8+ T cell epitope recognition paradigms. Science. 2013; 340 (6135) : 1237874. 5 Sanders RW, van Gils MJ, Derking R, et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by nativelike envelope trimers. Science 2015;349:aac4223.6 So Youn Shin. Recent update in HIV vaccine development. Cin Exp Vaccine Res.2016;5:6-117 Barton F. Haynes. New approaches to HIV vaccine development. Curr Opin
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 《一体式地下水表阀门井应用技术规范》(征求意见稿)
- 人教宁夏 九年级 下册 语文 第二单元《 综合性学习》习题课 课件
- 人教山西 九年级 下册 语文 第二单元《 变色龙》习题课 课件
- 人教陕西 九年级 下册 语文 第二单元《 单元写作》习题课 课件
- 人教山西 九年级 下册 语文 第一单元《 山西中考题型专练》习题课 课件
- 人教陕西 九年级 下册 语文 期末特训 专题5 情境化基础综合
- 人教版部编版小学语文一年级下册 4 猜字谜 教学设计-教案29
- 铁路路外培训
- 人教版一年级上册数学第一单元《准备课》试卷2
- 交货订单合同范例范例
- (高清版)辐射供暖供冷技术规程JGJ142-2012
- 新教科版六年级下册科学课件3 宇宙 第6课 浩瀚的宇宙
- JTT 1295—2019道路大型物件运输规范_(高清-最新)
- 电缆原材料检验规范
- 土壤固化土施工技术导则
- VAR模型Johansen协整检验在eviews中的具体操作步骤及结果解释
- 冷冻面团项目市场分析
- 北工大电子课程设计报告数电自行车里程表.
- 加油站法律法规符合性评价
- 5外科--丹毒下肢丹毒中医诊疗方案2017年版
- 数学物理方法第十一章PPT课件
评论
0/150
提交评论